Rocket Pharmaceuticals, Inc. (RCKT) Financials
RCKT Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 566.3 million | 73.8 million |
2023-09-30 | 598.8 million | 57.7 million |
2023-06-30 | 461.8 million | 58.8 million |
2023-03-31 | 514.8 million | 55.9 million |
RCKT Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -34.0 million | 9.9 million |
2023-09-30 | -61.8 million | 10.3 million |
2023-06-30 | -55.0 million | 10.2 million |
2023-03-31 | -60.6 million | 8.9 million |
RCKT Net Income
No data available :(
RCKT Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 373.2 million | - | 25.0 million |
2023-09-30 | 437.2 million | - | 25.2 million |
2023-06-30 | 307.0 million | - | 25.4 million |
2023-03-31 | 331.1 million | - | 25.4 million |
RCKT Shares Outstanding
RCKT Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 4.6 million | 41.7 million | 21.5 million | - |
2023-09-30 | 4.7 million | 46.8 million | 18.6 million | - |
2023-06-30 | 4.1 million | 51.4 million | 17.4 million | - |
2023-03-31 | 3.0 million | 46.4 million | 15.8 million | - |
RCKT Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 10.3 million | 5.2 million |
2023-09-30 | - | 1.8 million |
2023-06-30 | - | 1.7 million |
2023-03-31 | - | 1.7 million |
RCKT
Price: $23.36
52 week price:
Earnings Per Share: -2.92 USD
P/E Ratio: -9.06
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 607900
Market Capitalization: 2.2 billion